QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ETNB

89bio (ETNB) Stock Price, News & Analysis

$11.64
+0.33 (+2.92%)
(As of 04:00 PM ET)
Today's Range
$11.01
$11.69
50-Day Range
$8.13
$13.77
52-Week Range
$6.57
$22.93
Volume
840,132 shs
Average Volume
1.37 million shs
Market Capitalization
$1.09 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.83

89bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
150.5% Upside
$28.83 Price Target
Short Interest
Bearish
11.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of 89bio in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$20.72 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.20) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.29 out of 5 stars

Medical Sector

544th out of 938 stocks

Pharmaceutical Preparations Industry

252nd out of 433 stocks

ETNB stock logo

About 89bio Stock (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock Price History

ETNB Stock News Headlines

89bio (NASDAQ:ETNB) Given "Buy" Rating at HC Wainwright
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
89bio (NASDAQ:ETNB) Stock Price Up 3.5%
ETNB Apr 2024 12.500 put
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
89bio price target raised by $8 at Evercore ISI, here's why
89bio Inc.
ETNB Mar 2024 20.000 put
ETNB Mar 2024 20.000 call
89bio Inc
ETNB Mar 2024 15.000 call
ETNB Mar 2024 7.500 put
See More Headlines
Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.83
High Stock Price Target
$37.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+147.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-142,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.75 per share

Miscellaneous

Free Float
89,387,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
1.04
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 58)
    CEO & Director
    Comp: $990.52k
  • Mr. Quoc Le-Nguyen (Age 56)
    Chief Technical Operations Officer & Head of Quality
    Comp: $654.44k
  • Dr. Harry Mansbach M.D. (Age 59)
    Chief Medical Officer
    Comp: $691.87k
  • Mr. Ryan Stephen Martins (Age 45)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan C.P.A. (Age 58)
    Senior Vice President of Finance & Principal Accounting Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations & Corporate Communications
  • Ms. Amanda Kurihara
    Vice President of People & Culture
  • Ms. Yun Bai Ph.D.
    VP and Head of Chemistry, Manufacturing & Controls ( CMC )
  • Ms. Melissa Abel
    Senior Vice President of Commercial Strategy
  • Mr. Paul Shin
    Senior Vice President of R&D Operations

ETNB Stock Analysis - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price target for 2024?

6 Wall Street research analysts have issued 12 month target prices for 89bio's shares. Their ETNB share price targets range from $14.00 to $37.00. On average, they expect the company's share price to reach $28.83 in the next twelve months. This suggests a possible upside of 150.5% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2024?

89bio's stock was trading at $11.17 on January 1st, 2024. Since then, ETNB shares have increased by 3.0% and is now trading at $11.51.
View the best growth stocks for 2024 here
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) released its earnings results on Thursday, February, 29th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.01.

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89bio's major shareholders?

89bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RTW Investments LP (5.99%), Vanguard Group Inc. (4.62%), Vanguard Group Inc. (4.61%), BVF Inc. IL (4.34%), Frazier Life Sciences Management L.P. (2.15%) and Federated Hermes Inc. (2.11%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETNB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners